In fact, researchers have long documented how certain emotional reactions from family members correlate with higher relapse rates for people who have a diagnosis of schizophrenia.
But some studies on the nonconfrontational approaches, described by independent researchers not doing the interventions themselves as statistically sound, have shown the Johnson model to be both less effective in getting an addict into treatment and linked to higher relapse rates, compared with softer approaches, including one called "carefrontation".
Patients with TTH had higher relapse rates than migraine patients (77 vs. 23%, respectively), and analgesic overusers had higher relapse rates than ergot and triptan overusers (58 vs. 18 and 22%) [41].
Thus, a higher relapse rate may be expected if individuals with no or some improvement of headache frequency after successful withdrawal are included in the analysis.
Furthermore, the removed tuberculosis patients who often have higher relapse rate may travel into another region; or the infectious individuals may also travel.
Double-positive (both anti-GBM antibody and ANCA antibody positive) patients have higher relapse rate than those with anti-GBM antibody alone [1].
Non-remission rates to pharmacotherapy for anxiety disorders are related to higher relapse rates, decreased quality of life and greater functional impairment.
Consequently, patients with co-morbid substance abuse have a higher rate of re-hospitalisation, reduced psychosocial functions, less patient concordance with treatment, as well as a higher relapse rate than patients without such substance consumption [23].
In recent years, certain C. difficile types have become highly represented among clinical isolates and are associated with outbreaks of increased disease severity, higher relapse rates and an expanded repertoire of antibiotic resistance.
During the follow-up period, patients with LUXN mRNA-positive CTC at 3 time points had a higher relapse rate and a shorter DFS and OS than those without.
It remains unclear if they have a higher level of depressive symptoms, a higher risk of non-response, a poorer prognosis and a higher relapse rate compared to non-anxious depressed (non-AD) patients.
